----
Current ValuationThe current P/E ratio is -1.16, below the reasonable range, cheaper than 84.67% of the time in the past 1 years, and the industry ranks 10/14, the industry Median -0.09.
-1.16xP/E
$0.28Stock price
$-0.24Earnings per share
-1.16xP/E
Stock price$0.28Earnings per share$-0.24
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.75x
- Typical range
- -1.05x–-0.42x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
09182736
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x10x20x30x40x50x
| Name/Symbol | |||
|---|---|---|---|
AHCOUSAdaptHealth | -3.65x | 145.62% | $831.70M |
AHGUSAkso Health | -37.54x | -- | $700.86M |
COSMUSCosmos Health | -1.16x | 65.08% | $28.25M |
ACHUSAccendra Health | -0.06x | 89.52% | $16.83M |
ZSTKUSZeroStack | -0.05x | 90.76% | $8.68M |
POMUSPomdoctor | -0.16x | -- | $8.37M |
MEDSUSDataMeds AI | -0.09x | -- | $8.33M |
ATPCUSAgape ATP | -1.37x | -- | $1.55M |
VRAXUSVirax Biolabs | -0.21x | 52.53% | $1.07M |
BIMIUSBIMI International Medical | -- | -- | $5.58K |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
